Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy

RegulatoryapprovedSimufilamPositive

AI Analysis

Summary

Filana Therapeutics announced the FDA has lifted a clinical hold on Simufilam, allowing the company to proceed with a Phase 2a study in tuberous sclerosis complex-related epilepsy.

Clinical Trial Data

Phase

Outcome Details

FDA lifted clinical hold on Simufilam

Importance:7/10

Sentiment:

0.80

clinical hold liftedFDAepilepsyTSCPhase 2a

Related Companies

$FLNA

Read the original article

Published by yahoo_finance on September 22, 2026 12:00 PM

Read Original